clinical trial · NCT07813637
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
Prostate CancerCastration-Resistant Prostate Cancer (CRPC)Metastatic Prostate CancerMetastatic Castration-Resistant Prostate Cancer PatientsJANX013JANX007JANX013JANX007
brief summary
This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).
started
Sep 10, 2026
primary completion
Jul 1, 2029
completion
Jul 1, 2030
last updated
Sep 17, 2026
official title
A Phase 1 Open-Label, Multicenter Study of JANX013 Combined With JANX007 in Participants With Metastatic Castration Resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol